Search

Displaying results 4801 - 4810 of 9670 in total
  1. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.

  2. Drug

    Enpatoran

    go.drugbank.com/drugs/DB16501
    Investigational

    It was investigated for systemic lupus erythematosus and cutaneous lupus erythematosus in completed trials (NCT04647708 and NCT05162586) and in a recruiting trial (NCT05540327). … Enpatoran (M5049) was under investigation in clinical trials for various conditions.

  3. Drug

    Cambinol

    go.drugbank.com/drugs/DB15493
    Experimental

    This activity is currently being investigated for its use as a cancer treatment.

  4. Drug

    1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine

    go.drugbank.com/drugs/DB01562
    ExperimentalIllicit

    It is sold as a "synthetic heroin."

  5. Drug

    Clinafloxacin

    go.drugbank.com/drugs/DB14025
    Experimental

    It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.

  6. Drug

    TGAAC09

    go.drugbank.com/drugs/DB06363
    Investigational

    It was under investigation in clinical trials NCT00482027 and NCT00888446 for the treatment of HIV Infection.

  7. Drug

    MLN3897

    go.drugbank.com/drugs/DB06505
    Experimental

    MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

  8. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.

  9. Drug

    Ridogrel

    go.drugbank.com/drugs/DB01207
    Experimental

    Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction.

  10. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other … Because Hly is only active at an acidic pH, similar to listeriolysin O, the deletion of urease C was also beneficial for Hly to have optimal bioactivity in the phagosome.